Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study

The Lancet Psychiatry

Volumn 4, Issue 5, 2017, Pages 378-388

  Agger, Johanne L ^a   Schröder, Andreas ^a   Gormsen, Lise K ^a   Jensen, Jens S ^a   Jensen, Troels S ^a   Fink, Per K ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; IMIPRAMINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; APPETITE DISORDER; ARTICLE; CLINICAL OUTCOME; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH STATUS; HEART PALPITATION; HOSPITAL PHARMACY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; PAIN; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSOMATIC DISORDER; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEDATION; SIDE EFFECT; SKIN BRUISING; SLEEP DISORDER; SUBDURAL HEMATOMA; SWEATING; UNIVERSITY HOSPITAL; URINE RETENTION; VISUAL DISORDER; WEIGHT CHANGE; XEROSTOMIA; CLINICAL TRIAL; DENMARK; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; SOMATOFORM DISORDER; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DENMARK; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIPRAMINE; LINEAR MODELS; MALE; MIDDLE AGED; SOMATOFORM DISORDERS; TREATMENT OUTCOME;

EID: 85017351881     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30126-8     Document Type: Article

References (30)

1. 1 Henningsen, P, Zipfel, S, Herzog, W, Management of functional somatic syndromes. Lancet 369 (2007), 946–955.
2. 2 Barsky, AJ, Orav, EJ, Bates, DW, Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 62 (2005), 903–910.
3. 3 Wessely, S, Nimnuan, C, Sharpe, M, Functional somatic syndromes: one or many?. Lancet 354 (1999), 936–939.
4. 4 Ford, AC, Quigley, EM, Lacy, BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 109 (2014), 1350–1365.
5. 5 Hauser, W, Walitt, B, Fitzcharles, MA, Sommer, C, Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther, 16, 2014, 201.
6. 6 Kleinstauber, M, Witthoft, M, Steffanowski, A, van Marwijk, H, Hiller, W, Lambert, MJ, Pharmacological interventions for somatoform disorders in adults. Cochrane Database Syst Rev, 11, 2014 CD010628.
7. 7 Ruepert, L, Quartero, AO, de Wit, NJ, van der Heijden, GJ, Rubin, G, Muris, JW, Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev, 8, 2011 CD003460.
8. 8 Hauser, W, Wolfe, F, Tolle, T, Uceyler, N, Sommer, C, The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 26 (2012), 297–307.
9. 9 Pae, CU, Marks, DM, Patkar, AA, Masand, PS, Luyten, P, Serretti, A, Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother 10 (2009), 1561–1570.
10. 10 Wolfe, F, Walitt, BT, Katz, RS, Lee, YC, Michaud, KD, Hauser, W, Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain 17 (2013), 581–586.
11. 11 Moore, RA, Derry, S, Aldington, D, Cole, P, Wiffen, PJ, Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev, 12, 2012 CD008242.
12. 12 Finnerup, NB, Attal, N, Haroutounian, S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14 (2015), 162–173.
13. 13 Schroder, A, Sharpe, M, Fink, P, Medically unexplained symptom management. Lancet Psychiatry 2 (2015), 587–588.
14. 14 Fink, P, Schroder, A, One single diagnosis, bodily distress syndrome, succeeded to capture 10 diagnostic categories of functional somatic syndromes and somatoform disorders. J Psychosom Res 68 (2010), 415–426.
15. 15 Lam, TP, Goldberg, DP, Dowell, AC, et al. Proposed new diagnoses of anxious depression and bodily stress syndrome in ICD-11-PHC: an international focus group study. Fam Pract 30 (2013), 76–87.
16. 16 Fink, P, Toft, T, Hansen, MS, Ornbol, E, Olesen, F, Symptoms and syndromes of bodily distress: an exploratory study of 978 internal medical, neurological, and primary care patients. Psychosom Med 69 (2007), 30–39.
17. 17 Fjorback, LO, Arendt, M, Ornbol, E, et al. Mindfulness therapy for somatization disorder and functional somatic syndromes: randomized trial with one-year follow-up. J Psychosom Res 74 (2013), 31–40.
18. 18 Schroder, A, Rehfeld, E, Ornbol, E, Sharpe, M, Licht, RW, Fink, P, Cognitive-behavioural group treatment for a range of functional somatic syndromes: randomised trial. Br J Psychiatry 200 (2012), 499–507.
19. 19 Sharpe, M, Walker, J, Williams, C, et al. Guided self-help for functional (psychogenic) symptoms: a randomized controlled efficacy trial. Neurology 77 (2011), 564–572.
20. 20 Straube, S, Derry, S, Moore, RA, McQuay, HJ, Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 49 (2010), 706–715.
21. 21 McCullagh, P, Regression models for ordinal data. J R Statist Soc Ser B Methodol 42 (1980), 109–142.
22. 22 Abdul-Baki, H, El, H, Elzahabi, L, et al. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. World J Gastroenterol 15 (2009), 3636–3642.
23. 23 Drossman, DA, Toner, BB, Whitehead, WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125 (2003), 19–31.
24. 24 Limsrivilai, J, Charatcharoenwitthaya, P, Pausawasdi, N, Leelakusolvong, S, Imipramine for treatment of esophageal hypersensitivity and functional heartburn: a randomized placebo-controlled trial. Am J Gastroenterol 111 (2016), 217–224.
25. 25 Rahimi, R, Nikfar, S, Rezaie, A, Abdollahi, M, Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 15 (2009), 1548–1553.
26. 26 Holbech, JV, Bach, FW, Finnerup, NB, Brosen, K, Jensen, TS, Sindrup, SH, Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial. Pain 156 (2015), 958–966.
27. 27 Sluka, KA, Clauw, DJ, Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience 338 (2016), 114–129.
28. 28 Yunus, MB, Editorial review: an update on central sensitivity syndromes and the issues of nosology and psychobiology. Curr Rheumatol Rev 11 (2015), 70–85.
29. 29 Schroder, A, Oernboel, E, Licht, RW, Sharpe, M, Fink, P, Outcome measurement in functional somatic syndromes: SF-36 summary scores and some scales were not valid. J Clin Epidemiol 65 (2012), 30–41.
30. 30 Brosen, K, Nielsen, PN, Brusgaard, K, Gram, LF, Skjodt, K, CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 47 (1994), 221–225.